Determination of arsenic metabolites in urine of acute promyelocytic leukemia patients treated with arsenic trioxide by HPLC-HG-AFS
WANG Wen-jing
HU Shuang
GUO Mei-hua
GAO Chun-lu
HAI Xin
Abstract：Objective: To establish a method to determinate arsenic metabolites (AsⅢ, DMA, MMA, AsV) in urine of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide by HPLC-HG-AFS, for studying the morphological categories, distributions and change of arsenic metabolites in urine of APL patients and investigating the relationship between the curative effect and side effects. Methods: Chromatographic column: Hamilton PRP-X100 column (4.1 mm × 250 mm, 10 μm); mobile phase:CH3COONa (13 mmol·L-1)-NaH2PO4(3 mmol·L-1)-KNO3(4 mmol·L-1)-EDTA·2Na (0.2 mmol·L-1), pH = 6; flow rate: 1.0 mL·min-1;column temperature: 30 ℃; injection volume: 100 μL. Reductant: 3% KBH4(m/v)-0.5% KOH (m/v), the carrier fluid: 10% HCl (v/v). AFS conditions: main current: 80 mA, auxiliary current: 40 mA, shielding gas flow rate: 900 mL·min-1; carrier gas flow rate: 300 mL·min-1;negative high voltage: 300 V; pump speed: 65 r·min-1. Results: The concentration of AsⅢ, DMA, MMA, AsVin (2.0 – 100.0) ng·mL-1 showed good linear relationships (R2≥ 0.999 1). Spiked recovery rates were above 82%, and the precision was good. This method was used to determinate concentration of arsenic metabolites in urine of APL patients treated with arsenious acid. Conclusion: The accuracy and sensitivity of this method are high, the operation is simple, the reliability is good and the cost is low, which is suitable for the determination of arsenic metabolites in urine of APL patients.
Keywords：Arsenic trioxideArsenic metaboliteHPLC-HG-AFSAcute promyelocytic leukemiaUrine
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 5-8,12 )